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Abstract
The evolution of multiple antibiotic resistance is an increasing global problem. Resistance mutations are known to impair
fitness, and the evolution of resistance to multiple drugs depends both on their costs individually and on how they
interact—epistasis. Information on the level of epistasis between antibiotic resistance mutations is of key importance to
understanding epistasis amongst deleterious alleles, a key theoretical question, and to improving public health measures.
Here we show that in an antibiotic-free environment the cost of multiple resistance is smaller than expected, a signature of
pervasive positive epistasis among alleles that confer resistance to antibiotics. Competition assays reveal that the cost of
resistance to a given antibiotic is dependent on the presence of resistance alleles for other antibiotics. Surprisingly we find
that a significant fraction of resistant mutations can be beneficial in certain resistant genetic backgrounds, that some double
resistances entail no measurable cost, and that some allelic combinations are hotspots for rapid compensation. These
results provide additional insight as to why multi-resistant bacteria are so prevalent and reveal an extra layer of complexity
on epistatic patterns previously unrecognized, since it is hidden in genome-wide studies of genetic interactions using gene
knockouts.
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Introduction
Epistasis occurs when the phenotypic effect of a mutation in a
locus depends on which mutations are present at other loci. When
the phenotype of interest is fitness, the existence of such genetic
interactions can constrain the course of evolution. The strength
and form of epistasis is relevant for the evolution of sex, buffering
of genetic variation, speciation and the topography of fitness
landscapes. While epistasis between gene deletions [1,2] has been
the focus of recent research, interactions between randomly
selected alleles, which are of the greatest evolutionary interest has
not [3]. Since mutations that confer antibiotic resistance are
known to affect bacterial fitness, levels of epistasis amongst such
mutations may determine how multiple resistance evolves. Such
knowledge can be used to understand and predict what type of
resistance mutations are likely to be segregating in microbial
populations [4]. To understand and predict the evolution of
multiple resistance it is of key importance to know how the fitness
of sensitive and resistance bacteria is affected in different
environments, particularly both in the presence and in the absence
of drugs. Recent studies have shown that interactions exist
amongst pairs of antibiotics, i.e. resistance to one drug affects
the action of another drug [5,6]. In particular the combination of
pairs of drugs has been studied and the combinations have been
characterized as additive, synergistic, antagonistic or suppressive.
Importantly it has been found that in certain drug combinations
(suppressive) one of the antibiotics may render the treatment more
effective against its resistant mutant than against the wild type [6].
However, we are lacking data on genetic interactions amongst
single nucleotide mutations conferring antibiotic resistance in a
drug free environment, i.e. the cost of multiple resistance. With the
occurring increase in frequency of multiple resistant bacteria and
the public health problems associated with it, knowledge on the
type and strength of epistasis is of most importance in
understanding the evolution of multiple resistance and, ultimately,
the planning of new strategies for human intervention.
One can think that a way to halt the spread of resistance to a
given antibiotic is to stop the use of that antibiotic. In the absence
of the antibiotic for which resistance has been acquired, antibiotic-
resistance mutants have a fitness cost when compared to sensitive
bacteria [7,8]. However, when infection is not resolved, a common
strategy is to continue treatment with a different antibiotic to
which the infecting bacteria are still susceptible. Unfortunately this
strategy has led to rapid increase in multiple-drug resistance and
not to the loss of resistance to the first treatment, as it would be
desired [9]. This raises the possibility that multi-resistant mutations
are not independent. If so, when resistance first develops the
following question should be asked: if a pathogenic strain is
resistant to antibiotic X, which antibiotic should be administered
as a second treatment? Clearly, the strategy will depend not only
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on knowledge about the fitness costs of single resistance mutations
but also on the level of genetic interactions – epistasis - between
the alleles that underlie those phenotypes. When epistasis exists, it
can be positive (antagonistic or alleviating) or negative (synergistic
or aggravating). If strong negative epistasis amongst drug
resistance alleles is found, then the cost of multiple resistances is
high and one can expect multi-drug resistant microbes to be
counter selected and disappear very rapidly in the absence of
either drug. On the contrary, a much more worrying scenario is
the existence of positive epistasis, for it implies that the expected
time for elimination of multiple resistance, even if antibiotic
pressure is inexistent, will be much longer and multiple resistant
bacteria are expected to accumulate in the population.
Here we quantify the degree of genetic interactions on cellular
fitness in an antibiotic free environment for point mutations which
confer resistance to commonly used antibiotics of three different
classes. We have focused on resistances to: (i) the quinolone
nalidixic acid, which inhibits DNA replication by binding to DNA
gyrase; (ii) rifampicin, which belongs to the rifamycins class of
antibiotics that bind to the b-subunit of RNA polymerase thereby
inhibiting transcription; and (iii) streptomycin, an aminoglycoside
that binds to the ribosome and inhibits elongation of protein
synthesis [10]. We find that epistasis is allele specific and that the
vast majority of allelic combinations exhibit positive epistasis. The
costs of double resistance are therefore smaller than what one
would expect if they were independent. Interestingly we found
several cases of sign epistasis, which implies that mutations
conferring resistance to a new antibiotic are compensatory, i.e.
alleviate the cost of resistance present on another locus.
Results
Single-resistant mutants’ fitness costs
To study the degree of epistatic interactions amongst alleles that
confer antibiotic resistance we started by selecting a series of
Escherichia coli spontaneous mutants resistant to commonly used
antibiotics of 3 different classes: nalidixic acid, rifampicin, and
streptomycin (Methods). From a panel of 120 sequenced clones
that carry a single nucleotide change, we obtained 19 different
classes of clones (Table S1) with spontaneous mutations in gyrA,
rpoB and rpsL, which are the correspondent common target genes
of resistance to nalidixic acid, rifampicin, and streptomycin,
respectively. Resistant bacteria with mutations in the same amino
acids as those collected here are segregating in microbial
populations [4,11]. We should notice that our procedure for
isolating clones carrying antibiotic resistance requires that viable
colonies of resistant bacteria can be formed and detected. Any
mutations that can arise and cause very high fitness costs cannot
therefore be accounted for in this study. Given that highly
deleterious mutations are unlikely to segregate in natural
populations [4], genetic interactions amongst such mutations are
likely to be of less clinical importance, unless these can be very
easily compensated for.
We determined the cost of resistance of each of the clones in the
absence of antibiotics. This was performed by measuring relative
competitive fitness of the resistant strains against a marked
sensitive strain through a competition assay in liquid LB medium
without antibiotics [12] (Methods). Figure 1A shows the
distribution of fitness costs of each of the mutants. The genotype
of each mutation as well as its fitness costs are provided in Table
S1. On average the cost of antibiotic resistance was 9%. A
Kolmogorov-Smirnov test does not reject the exponential
distribution (P= 0.85), a commonly used model to describe the
distribution of deleterious mutations in several organisms [13].
Mutations that confer resistance to nalidixic acid had a lower
average fitness cost (3%) than streptomycin or rifampicin (13%
and 9%, respectively). Similar levels of fitness cost were found
previously in resistant mutants of Mycobacterium tuberculosis [4,14]
and E. coli [15,16].
Epistasis between deleterious mutations that confer
antibiotic resistance
To study the fitness cost of double resistance and measure
epistasis we constructed by P1 transduction all possible pairwise
combinations (103) between different resistance alleles. These
correspond to 5611 streptomycin/rifampin, 563 streptomycin/
nalidixic acid and 1163 rifampin/nalidixic acid possible combi-
nations. We measured the fitness of the obtained double resistant
by competition assays, determined its cost and compared it with
the cost that would be predicted if there was no epistasis. Figure 1B
shows that the average cost of double resistance is less than twice
the average cost of a single resistance (compare with Figure 1A),
indicating positive epistasis. Fitness of double resistance was used
to calculate pairwise epistasis. Pairwise epistasis, e, between locus A
and B can be measured as follows [17]. If WAB is the fitness of the
wildtype, WAb, WaB are the fitnesses of each of the single mutants
and Wab that of the double mutant then:
e~WABWab{WAbWaB:
When the value of the costs is small then this measure becomes
very similar to the difference between the cost of double resistance
and the sum of the costs of each resistance.
Strikingly, the majority of mutations show positive epistasis.
68% of the points are above the line in Figure 2A and from the
clones that show significant epistasis 15% show negative epistasis
and 42% show positive epistasis. The later ones correspond to
clones where the cost is less than the sum of the costs of each
resistance (see also Figure 2C for the specific combinations of
alleles showing significant positive epistasis).
It has been suggested from theoretical modeling of RNA
secondary structures and from studies in digital organisms –
Author Summary
Understanding the nature of genetic interactions, known
as epistasis, is crucial in biology. The strength and type of
epistasis is relevant for the evolution of sex, buffering of
genetic variation, speciation, and the topography of fitness
landscapes. While epistasis between gene deletions has
been the recent focus of research, interactions between
randomly selected alleles, which are of the greatest
evolutionary interest, have not. We have studied the
strength and type of epistasis amongst alleles that confer
antibiotic resistance and have found that: in an antibiotic-
free environment, the cost of multiple resistance is smaller
than expected—a signature of pervasive positive epistasis
amongst alleles that confer resistance to antibiotics;
epistatic interactions are allele specific; a significant
fraction of resistant mutations can be beneficial in certain
resistant genetic backgrounds; some double resistances
entail no measurable cost; and some allelic combinations
are hotspots for rapid compensation. Overall, our findings
provide added reasoning as to why multi-resistance is so
difficult to eradicate. Importantly, our results of allelic-
specific epistasis reveal an extra layer of complexity on
epistatic patterns previously unrecognized.
Epistasis and Drug Resistance
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computer programs that mutate and evolve- [18] that epistasis and
the fitness effect of mutations may be correlated, such that
mutations with larger effects are more epistatic. In our data we
find significant correlations between the strength of epistasis
(deviation from zero in absolute value) and the costs of the
mutations (Pearson’s correlation r = 0.61, P,0.001), which
support this theoretical prediction. We also find a marginally
significant correlation between the value of epistasis, e, and the
cost of the mutations (Pearson’s correlation r = 0.19, P = 0.06).
Figure 2B shows the distribution of the e values, the median is
significantly positive (median=0.025, Bootstrap 95% CI [0.016;
0.032]), and its value corresponds to about 1/3 of the average cost of
Figure 1. Distribution of fitness costs of single and double mutants indicative of positive epistasis. (A) Distribution of fitness costs of
clones carrying single point mutations that confer resistance to streptomycin (black), rifampicin (dark grey) and nalidixic acid (light grey). (B)
Distribution of fitness costs of clones carrying double resistance to streptomycin/rifampicin (black), rifampicin/nalidixic acid (dark grey) and
streptomycin/nalidixic acid (light grey). The mean fitness cost of double resistants is less than twice the mean cost of single resistance mutations.
doi:10.1371/journal.pgen.1000578.g001
Figure 2. Evidence for positive epistasis. (A) Relation between the observed fitness of the double resistance genotypes and the expected fitness
under the assumption of no epistasis. (B) Distribution of the epistasis level e, whose median is 0.025 with bootstrap confidence interval [0.016, 0.032],
showing positive epistasis. (C) Allelic dependence of epistasis between the rpsL, rpoB and gyrA (positive epistasis in light grey, negative dark grey and
not significant in white. Black indicates combinations of alleles for which there was a low efficiency of transduction - synthetic sub-lethals).
doi:10.1371/journal.pgen.1000578.g002
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each single mutation. From the allelic combinations for which there is
significant epistasis (53%), only 27% give rise to negative epistasis,
whereas 73% of these combinations result in positive epistasis.
Epistatic interactions were observed more frequently between
mutations in gyrA and in rpsL, with high frequency of positive epistasis
but also extreme cases of negative epistasis (synthetic sub-lethal,
Figure 2C). Combination of gyrA and rpoB mutations produced the
lowest frequency of negative epistasis (6%), which suggests that the
sequential prescription of antibiotics leading to these resistances may
easily result in multi-resistance development.
Focusing on the mutations we notice that the interactions are
not gene but allele specific. For example R529H and H526L
mutations in rpoB notably showed very high negative epistasis
frequency, whereas four other mutations (D516V, H526N, I572F
and S512F) in the same gene showed no negative epistasis
regardless of the combination, and D516V and I572F mutations
revealed high frequency of positive epistasis. The latter are
potential candidates to segregate in natural populations. The rpoB
H526D mutation is a specific example where its epistasis is highly
dependent on the particular allele of the second mutation: rpoB
H526D interacts positively with rpsL K43N, but negatively with rpsL
K43T. Interestingly, the rpoB H526D mutation has been found in
multi-drug resistant M. tuberculosis strains and also in this organism
its cost was shown to depend on the genetic background [4]. This
suggests two important predictions: that we should find resistance
alleles with strong positive interaction segregating at higher
frequencies (such as rpoB H526D/rpsL K43N) in natural popula-
tions and that these genetic interactions should also apply to
microorganisms other than E. coli.
Sign epistasis in antibiotic resistance mutations
Recently it has been shown that an important type of epistasis,
which is known as sign epistasis [19], may constrain the evolution
of resistance to high penicillin concentrations [20]. Sign epistasis
happens when the sign of the fitness effect of a mutation
(deleterious or beneficial) is itself epistatic, i.e. sign epistasis exists
when a mutation is deleterious on some genetic backgrounds but
beneficial on others. This form of epistasis, if common, may give
rise to multiple peaks on the fitness landscape. In the context of
antibiotic resistance, the implication is simple: if sign epistasis is
pervasive then it will be much more difficult to move from a
scenario of multiple drug resistance to a scenario where all the
bacteria are sensitive, even if antibiotic selection pressure is
stopped. Experimental evolution studies have shown that, within
hundreds of generations, mutations which compensate for the cost
of antibiotic resistance (compensatory) are more likely to occur
[16,21,22] than revertants [14]. This suggests that sign epistasis
might have an important role for the evolution of antibiotic
resistance. Within the allelic combinations studied, 12% of our
clones showed unexpected sign epistasis between drug resistance
alleles. This corresponds to double mutants that have a fitness
bigger than the fitness of at least one of the single mutants
(Figure 3), and here it means that the mutation conferring
resistance to a new antibiotic is beneficial (compensatory) when in
a genetic background that contains a mutation conferring
resistance to a different antibiotic. This is the worst possible
scenario for the host and the best possible for the microbe. Given
that a particular mutation was just selected by application of an
antibiotic, evolution by natural selection makes it likely that the
fixation of a mutation conferring resistance to another antibiotic
will occur, even if selective pressure is not applied. Specifically, we
find that the same mutation conferring streptomycin resistance
(rpsL K88E, Figure 3) can be compensated by different mutations
that confer rifampicin resistance showing that rifampicin treat-
ment should be avoided in patients infected with rpsL K88E
streptomycin resistant mutants. Given these results, knowledge of
Figure 3. Evidence for sign epistasis amongst alleles conferring resistance. Sign epistasis occurs when the fitness of the double mutant
(white bar) is greater than the fitness of at least one single mutant (dark grey and light grey bars). The genotypes of the double mutants where we
found sign epistasis are indicated below the bars and the P values of the Wilcoxon test are indicated above the bars.
doi:10.1371/journal.pgen.1000578.g003
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both the clinical history of patient antibiotic use as well as the
specific genotypes associated with a given resistance is recom-
mended for predicting the optimal clinical outcomes.
Another worrying class of clones that we found corresponds to
combination of double resistant mutations that entail no significant
cost. These are 6 out of the 103: rpsL K43R/gyrA D87G, rpsL
K43R/gyrA D87Y, rpoB H526N/gyrA D87G, rpoB H526N/gyrA
D87Y, rpoB D516V/gyrA D87Y, rpsL K43R/rpoB H526N. These
mutants have no disadvantage against the wild-type. Although this
constitutes a small percentage, it is nevertheless of extreme
importance since for these double mutants little, if any,
compensation is required for restoring the competitive ability of
the wild-type. Given the known association between the cost of
resistance mutations measured in the laboratory and the frequency
at which they are found in clinical settings has been demonstrated,
at least in M. tuberculosis [4], we predict that those combinations of
double mutations are the ones which are more likely to be found.
Future studies are planned to test this prediction, although it
should be noted that the target for resistance may vary between
species and environmental conditions [23]. In the opposite
extreme we found five clones for which the transduction efficiency
was very low (combinations shown in black, Figure 2C) which
might correspond to combinations of mutations that must entail
high fitness cost.
Level and pattern of epistasis in spontaneous double-
resistant clones
To make predictions about which resistance alleles are likely to
be segregating it is important to study the frequency at which they
spontaneously arise. To query which of the P1 transducted
mutants are likely to naturally occur and if these also show
pervasive epistasis we collected hundreds of spontaneous double
resistance mutants. From 289 clones that were sequenced, we
obtained 76 different genotypes, whose frequencies are given in
Figure 4. We performed a x2-square test to investigate the effects
of genetic background on the spectrum of mutations that
spontaneously arise. We observe that there are significant
differences between the types of new resistance mutations that
appear in certain resistant backgrounds and the wild-type sensitive
background (Table S2).
We measured the fitness of each of the different spontaneous
double resistant clones and compared it with the fitness in the
corresponding clones constructed by P1 transduction. 67 out of 72
spontaneous clones were not different from the P1 constructed
mutants (Figure S2), but surprisingly, five double resistant clones
(rpoB S531F/gyrA D87Y; rpsL K43T/rpoB H526Y; rpsL K88R/rpoB
H526D; rpsL K43R/rpoB S531F; rpoB I572F/rpsL K88R) had a
significantly higher fitness (Wilcoxon test, P,0.01). These five
spontaneous mutants have a higher fitness because they must have
acquired an extra mutation during their isolation which is
compensatory. To show that this is in fact the case we measured
the fitness of independent clones carrying the same resistance
mutations. For three of these haplotypes (rpsL K43T/rpoB H526Y,
rpsL K88R/rpoB H526D, rpsL K43R/rpoB S531F) we measured the
fitness of spontaneous clones which were obtained applying the
reversed antibiotic selection procedure. (i.e. the clones were now
isolated by selecting first for rifampicin and secondly for
streptomycin). A Wilcoxon-test revealed that the fitness values of
these new independent clones were not different from the
corresponding P1 clones, showing that the original spontaneous
clones carry a compensatory mutation. Given the reduced number
of generations in the procedure of generating spontaneous double
resistant mutants, observing a compensatory mutation is only
probable if such mutation has a very strong effect (sc). This is
because only with a large sc it will not be stochastically lost
(probability of fixation ,2sc), and can fix in such short time (time
to fixation ,1/sc) [24]. Indeed for the five mutants mentioned
above, the estimated fitness effect sc is very large, on average 0.09
(with the corresponding effects of each compensatory mutation
0.07; 0.13; 0.11; 0.07; 0.06). Adaptive mutations of such strong
effect emerging and fixing so rapidly in bacterial populations
under such small effective population size, is surprising given
previous estimates of effects of beneficial mutations (on average
0.01) [25]. A strong compensatory mutation must also have
occurred in the spontaneous clones carrying rpsL K43T/gyrA
D87G, rpsL K43N/gyrA D87G, rpsL K43T/gyrA D87Y and rpsL
K43N/gyrA D87Y mutations, which were determined as synthetic
sub-lethals by P1 transduction.
We calculated the e values for the 67 spontaneous clones where
we do not have evidences for extra compensatory mutations and
obtained the same trend as with the double mutants constructed
Figure 4. Mutational spectrum and frequency of spontaneous double resistance mutations. Given the genetic background of the first
mutation (column) the frequency of the second mutation (raw) appears as percentage in grey scale gradient. For a given background the percentage
of mutations in the second locus adds up to 100%, in most cases, except when the second mutation occurred in a different gene. The percentage of
the occurrence of each mutation in a wild-type background is also shown in the third column.
doi:10.1371/journal.pgen.1000578.g004
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by P1 transduction (58% showed significant epistasis from which
74% showed positive epistasis and 7% that had no significant cost
(Figure S3)). These results indicate that positive epistasis is also
pervasive in spontaneous mutants supporting the relevance of our
results. Additionally, there is evidence from epidemiological
studies that in M. tuberculosis environmental resistant isolates more
than 96% of the strains resistant to rifampicin have at least one
mutation in rpoB, 52 to 59% of the streptomycin resistant strains
have mutations in rpsL and 74 to 94% of the strains resistant to
ofloxacin or levofloxacin (quinolones like nalidixic acid used here)
have mutations in gyrA [26]. Also, the same type of mutations have
been isolated in E. coli [27] and in Salmonella enterica where 42% of
the isolates showed substitutions in gyrA at position S83 and 35% at
position D87 [28], that we show here to exhibit epistasis. Thus we
expect the traits observed to be relevant for the evolution of multi-
drug resistance acquired during treatment of infectious agents.
Discussion
Given the importance of epistasis in a variety of biological
features such as sex and recombination, buffering of genetic
variation, speciation, and the evolution of genetic architecture
[29], recent studies have focused on measuring genome-wide levels
of epistasis. However, typically only deletions or knockout
mutations were studied [1,2,30,31]. Here, albeit focusing in a
small number of genes, we measured epistasis on fitness at the
scale of the allele given that these may be the most common type
of mutations segregating in natural populations and because it also
allows us to study mutations in essential genes. Our results not only
show the significance of these interactions for the evolution of
antibiotic resistance but also reveal an extra layer of complexity on
epistatic patterns previously unpredicted, since it is hidden in
genome-wide studies of genetic interactions using gene knockouts.
The data obtained here revealed an average level of positive
epistasis, which differs strongly from the results of the degree of
epistasis among slightly deleterious mutations caused by random
transposon insertions in E. coli, where on average no epistasis was
found [30]. Positive epistasis has also been found in HIV-1 isolates
[32]. Since the data in that study was obtained by sampling
mutants from natural populations, comparisons between the
results obtained and those found here should be taken carefully.
We note nevertheless that some bias towards positive epistasis that
may be present in the HIV study is not present in our study, since
we constructed all possible pairwise combinations of double
mutants. It remains to be explored whether the type of mutations
(single nucleotide changes, deletions or tranpositions) can affect the
pattern of genetic interaction which can be observed. We predict
that it can since we show that the type of interactions is not gene
but allele specific. Positive epistasis was also detected when
studying interactions between rifampin and streptomycin resistant
mutants in Pseudomonas aeruginosa [33]. The pattern in E. coli
presented here and the results found in P. aeruginosa (even though
having a different genetic basis) [33] indicate that the presence of
positive epistasis amongst antibiotic resistance mutations is not
species specific. Furthermore epistatic interactions involving
fluoroquinolone resistance mutations in gyrA have also been found
in Streptococcus pneumoniae [34].
Although we have studied different classes of antibiotics that
affect different cell targets, our finding of pervasive epistasis can be
reflecting the fact that these target genes are part of the
fundamental flow from DNA to RNA to protein, and thus can
be considered to be working in the same pathway. Because these
affect highly conserved cell processes they should be relevant in
many different organisms. An interaction between some of these
genes has been described for specific traits, namely propagation of
bacteriophage T7 (interaction between rpsL and rpoB) and
mitomycin C resistance in E. coli (between rpoB and gyrA) [35,36].
Our data, both of spontaneous and P1 transducted double
resistant clones, also indicates the presence of sign epistasis in the
cost of multi-drug resistance involving rifampin, streptomycin and
nalidixic acid, that is, a small fraction of double resistant clones
showed a higher fitness than at least one of the corresponding
single resistant mutants. Sign epistasis implies that the fixation of
one mutation (for example by strong selection pressure of a given
antibiotic) may alter the adaptive path in both number and type of
subsequent beneficial mutations. Sign epistasis was also previously
found in the context of resistance to the antibiotic cefotaxime [20].
In this system, of the 120 possible mutational paths from the low
resistance to high resistance, only 18 can actually occur due to the
occurrence of sign epistasis. Although there are not many
examples in the literature [19], this one clearly shows the power
of sign epistasis in constraining protein adaptation.
Another interesting example in the context of this work is
bacterial adaptation to the cost of resistance through the
acquisition of new compensatory mutations. In such an adaptive
process it was observed that adaptive mutations which reduce the
cost of resistance to streptomycin in E. coli [37] and Salmonella
[12] are deleterious in the streptomycin-sensitive background and
therefore constitute an example of sign epistasis.
In this work we have determined the fitness effect of mutations
in the absence of antibiotics. Future studies should focus on
epistatic interactions when bacteria grow in the presence of
antibiotics, a condition already shown to be relevant to the
evolution of resistance [38,39].
Our results highlight the importance of determining the costs of
single and multiple resistances and, accordingly ordering allele
combinations by the degree of epistasis they exhibit. Given that at
the present time, infections are likely to be caused by microbes that
carry resistance to at least one drug, the strategy expected to give
the best outcome is one in which the next drug is the one leading
simultaneously to the resistant mutant with the biggest cost and
strongest negative epistasis. Another approach to prevent the
evolution of multidrug resistance would be to use drug
combinations (at certain concentrations) that select for sensitive
bacteria. This is a plausible scenario since it has been shown that
when competing in the presence of the two drugs, sensitive
bacteria outgrow resistant [6]. Our finding of pervasive positive
epistasis suggests one possible explanation for the difficulty of
eradicating multi-drug resistance in organisms like M. tuberculosis,
for which current treatments involve combinations of the same
drugs as studied here.
Methods
Bacterial strains and growth conditions
The strains used were Escherichia coli K12 MG1655 and
Escherichia coli K12 MG1655 Dara. All clones with antibiotic
resistant mutations were derived from the ancestral strain
Escherichia coli K12 MG1655. Escherichia coli K12 MG1655 Dara,
was used as reference for the competition fitness assay. The two
strains are distinguishable by phenotypic difference due to a
deletion in the arabinose operon: ara+ and Dara give rise to white
and red colonies, respectively, in tetrazolium arabinose (TA)
indicator agar [12]. The clones were grown at 37uC on plates
containing Luria-Bertani (LB) supplemented with agar and the
respective antibiotics. The antibiotic concentrations were 100 mg/
ml for rifampicin, 40 mg/ml for nalidixic acid and 100 mg/ml for
streptomycin. To estimate fitness costs competitions were
Epistasis and Drug Resistance
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performed during 24 hours in 50 ml screw-cap tubes containing
10 ml of LB medium at 37uC, with aeration (orbital shaker at 230
RPM). To estimate the frequency of each strain, in the beginning
and by the end of the competition, Tetrazolium Agar (TA)
medium containing 1% peptone, 0.1% yeast extract, 0.5% sodium
chloride, 1.7% agar, 1% arabinose and 0.005% Tetrazolium
chloride was used. All sets of dilutions were done in MgSO4 at a
concentration of 0.01 M.
Isolation of P1 transducted and spontaneous resistant
clones
The measure of two-locus epistasis requires the construction of
double mutants from single mutants, in order to obtain clones with
the same mutations alone and in combination. The antibiotics
chosen to isolate the mutants were rifampicin, nalidixic acid and
streptomycin. Sets of 40 single clones resistant to each antibiotic
were obtained by growing independent cultures of Escherichia coli
K12 MG1655, plating in Luria-Bertani (LB) agar medium
supplemented with each antibiotic and randomly selecting the
clones after 24 hours of incubation at 37uC. Each clone was streak
plated, and a single colony was grown in a screw-cap tube with
10 ml of LB medium supplemented with the respective antibiotic
and stored in 15% glycerol at 280uC. Generalized transduction of
the resistance mutations with bacteriophage P1 was performed as
described previously [40]. These mutations were obtained by
isolating spontaneous resistant clones and then using these as
donor or recipient strains for the construction of the double
mutants. Whereas in the great majority of clones the transduction
efficiency was high, in 5 combinations of clones it was extremely
low. These clones were termed synthetic sub-lethals and are
indicated on Figure 2C. For two combinations of double resistance
mutations, three independent clones were assayed for fitness. No
significant differences were observed (Kruskal-Wallis test) between
these clones.
Three single spontaneous clones, resistant to each antibiotic,
were used to put back the resistance on the wild-type sensitive
background through P1 transduction. We then measured in 5 fold
replicate competitions the fitnesses of each spontaneous mutant
and the corresponding single P1 transducted clone. Pairwise
comparisons, by Wilcoxon test, revealed no significant differences
between the single resistance clones constructed in different ways.
We exposed the single resistant clones to a second antibiotic to
select for spontaneous mutants resistant to two antibiotics. These
were obtained by culturing each clone carrying resistance
independently and plating in Petri-dishes with the two antibiotics.
Clones with the double resistance were picked randomly. All
spontaneous resistant clones were tested for a mutator phenotype
and those few with evidence of high mutation rate were
disregarded.
Detection of mutations
The main target genes for resistance to rifampicin, nalidixic acid
and streptomycin are rpoB, gyrA and rpsL, respectively. To know the
mutations that confer the obtained resistances, each target was
amplified and then sequenced. The primers used to amplify the
portion of the rpoB gene encoding the main set of mutations
conferring resistance to rifampicin were: 59-CGTCGT-
ATCCGTTCCGTTGG-39 and 59-TTCACCCGGATAACATC-
TCGTC-39; for gyrA gene, which encodes for the main set of
mutations conferring resistance to nalidixic acid, 59-TACAC-
CGGTCCACATTGAGG-39 and 59-TTAATGATTGCC-
GCCGTCGG-39; for rpsL gene, that encodes for the mutations
conferring streptomycin resistance, 59-ATGATGGCGGGAT-
CGTTG-39 and 59-CTTCCAGTTCAGATTTACC-39. The same
primers were used for sequencing straight from the PCR product.
Fitness assays
To measure fitness cost of the resistance mutations a
competition assay was done. The resistant mutants were competed
against a reference strain, Escherichia coli K12 MG1655 Dara in an
antibiotic free environment, in an approximate proportion of 1:1.
To do so, we grew both resistant and reference strains in LB liquid
medium for 24 hours at 37uC with aeration. Accurate values of
each strain initial ratio were estimated by plating a dilution of the
mixture in TA Agar plates. Competitions were performed in 50 ml
screw-cap tubes containing 10 ml of LB liquid medium by a
period of 24 hours at 37uC with aeration. By the end of this
competition process, appropriate dilutions were platted onto TA
agar plates to obtain the final ratios of resistants and reference
strains. The fitness cost of each mutant strain- i.e the selection
coefficient - was estimated as the per generation difference in
Malthusian parameters for the resistant strain and the marker
strain [12], discounted by the cost of the Dara marker. The fitness
cost was estimated as an average of four and five independent
competition assays for P1 and spontaneous resistant clones
respectively. No correlation was observed between the cost of
the resistance mutations and the frequency at which they arose
(Figure S1).
Measure of epistasis and statistical significance
Pairwise epistasis, e, can be measured assuming a multiplicative
model in which case: e=WABWab2WAbWaB, where Wij is the
fitness of the clone carrying alleles i and j and capital letters
represent the wild-type sensitive alleles. Error (se) of the value of e
is then estimated by the method of error propagation:
se~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Wab
2sWAB2zWAB2sWab2zWaB
2sWAb2zWAb
2sWaB2
q
:
Whenever the value of e was within the error we considered that
alleles a and b did not show any significant epistasis (we indicate
such combinations as white boxes labeled no epistasis in
Figure 2C).
From the distribution of values of e, provided in Figure 2B, we
calculated the median value of e and its 95% CI by bootstrap
where we took 1000 samples. We tested normality of the
distribution by a Shapiro-Wilk normality test (P = 0.024), and a
Wilcoxon test for the location in zero resulted in a P value of
P= 0.0006.
To query about the presence of sign epistasis in the data we
made pairwise comparisons between the fitness of each double
resistance clone and its corresponding single resistance clones
using a Wilcoxon test to assess if the fitness of the double resistant
was higher than the fitness of any of the single resistance clones.
The P values are indicated in Figure 3 for those combinations that
provided significant results, at 5% confidence level, after
Bonferroni correction (n= 2 comparisons). For some of the double
resistant clones created by P1 transduction that indicated the
presence of sign epistasis- see Figure 3- we also obtained
spontaneous double resistant mutants, that equally indicated
evidence for sign epistasis.
Epistasis is sometimes calculated assuming an additive model
[41]: e= cab2(ca+cb), such that it measures the deviation of the cost
of carrying double resistance from the sum of the costs of each
resistance. Since the values of the majority of the cost are small,
applying the multiplicative or the additive model leads to the same
conclusions, i.e. those combinations of alleles that lead to positive
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(negative) epistasis under the multiplicative model, also lead to
positive (negative) epistasis under the additive model. A Kolmo-
gorov-Smirnov comparing the distributions of e under multiplica-
tive model with e under the additive model results on P= 0.9. The
median value in the distribution of epistasis calculated under the
additive model is 0.025 with bootstrap 95% CI [0.015; 0.036] and
a Wilcoxon test for location strongly supports the presence of
positive epistasis: P = 0.00002. This shows that the same pattern
occurs applying either the multiplicative or the additive models.
To perform the statistical analysis we used the free software R:
http://www.r-project.org.
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